Mortality in children and adolescents vertically infected by HIV receiving care at a referral hospital in Vitoria, Brazil

BMC Infectious Diseases

Angélica Espinosa Miranda³  Eliana Zandonade¹  Sandra Fagundes Moreira-Silva² 

[1] Statistics Department, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil;Infectious Diseases Department, Nossa Senhora da Glória State Hospital (SI-HEINSG), Vitória, Espírito Santo, Brazil;Núcleo de Doenças Infecciosas, Federal University of Espírito Santo, Av. Marechal Campos, 1468, Vitória [29100-240], ES, Brazil

关键词: Causes of death;    Late diagnosis;    Mortality;    Children;    HIV;   

Others  :  1173930
DOI  :  10.1186/s12879-015-0893-0

 received in 2014-11-20, accepted in 2015-03-12,  发布年份 2015

【 摘 要 】

Background

Daily throughout 2011, about 900 new HIV infections occurred in children and 630 children died as a result of AIDS-related complications worldwide. Late diagnosis, mortality trends, causes of and risk factors for death were evaluated in vertically HIV-infected children.

Methods

A retrospective 11-year study was conducted with Brazilian vertically HIV-infected children and adolescents using patients’ charts. Medical records, death certificates and the Ministry of Health’s mortality database were verified for mortality and cause of death. Diagnoses were made according to the CDC Revised Classification System for HIV infection.

Results

Of 177 patients included, 97 were female (54.8%). Median age at admission was 30 months (IQR: 5–72 months). Median follow-up was 5 years (IQR: 2–8 years). After 11 years, 132 (74,6%) patients continued in follow-up, 11 (6.2%) had been transferred and 8 (4.5%) were lost to follow-up. Twenty-six deaths occurred (14,7%), the majority (16/26; 61.5%) in children <3 years of age. Death cases decreased over time and the distribution of deaths was homogenous over the years of evaluation. In 17/26 (65.4%) of the children who died, diagnosis had been made as the result of their becoming ill. Beginning antiretroviral therapy before 6 months of age was associated with being alive (OR = 2.86; 95% CI: 1.12–7.25; p = 0.027). The principal causes of death were severe bacterial infections (57%) and opportunistic infections (33.3%).

Conclusions

In most of the HIV-infected children, diagnosis was late, increasing the risk of progression to AIDS and death due to delayed treatment. The mortality trend was constant, decreasing in the final two years of the study. Bacterial infections remain as the major cause of death. Improvements in prenatal care and pediatric monitoring are mandatory.

【 授权许可】

   
2015 Moreira-Silva et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al.: AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000, 356:291-6.
• [2]Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13:1933-42.
• [3]Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, et al.: Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the perinatal AIDS collaborative transmission study, 1986–2004. Pediatrics 2007, 120:100-9.
• [4]Kapogiannis BG, Soe MM, Nesheim SR, Abrams EJ, Carter RJ, Farley J, et al.: Mortality trends in the US perinatal AIDS collaborative transmission study (1986–2004). Clin Infect Dis 2011, 53:1024-34.
• [5]Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-30.
• [6]El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al.: Strategies for Management of Antiretroviral Therapy (SMART) Study Group1: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-96.
• [7]Melo LS, Lacerda HR, Campelo E, Moraes E, Ximenes RA: Survival of AIDS patients and characteristics of those who died over eight years of highly active antiretroviral therapy, at a referral center in northeastern Brazil. Braz J Infect Dis 2008, 12:269-77.
• [8]Cardoso CA, Pinto JA, Candiani TM, Carvalho IR, Linhares RM, Goulart EM: The impact of highly active antiretroviral therapy on the survival of vertically HIV-infected children and adolescents in Belo Horizonte, Brazil. Mem Inst Oswaldo Cruz 2012, 107:532-8.
• [9]Candiani TM, Pinto J, Cardoso CA, Carvalho IR, Dias AC, Carneiro M, et al.: Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 2007, 23(Suppl 3):S414-23.
• [10]Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med 1994, 331:1173-80.
• [11]Matida LH, Ramos AN Jr, Moncau JE, Marcopito LF, Marques HH, Succi RC, et al.: AIDS by mother-to-child transmission: survival analysis of cases followed from 1983 to 2002 in different regions of Brazil. Cad Saude Publica 2007, 23(Suppl 3):S435-44.
• [12]Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS: Recomendações para terapia antirretroviral em crianças e adolescentes infectados pelo HIV: manual de bolso/Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS. (Série Manuais, n. 85). Ministério da Saúde, Brasília; 2009.
• [13]Lallemant M, Chang S, Cohen R, Pecoul B: Pediatric HIV – a neglected disease? N Engl J Med 2011, 365:581-3.
• [14]Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al.: Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009, 23:597-604.
• [15]Dias CF, Moreira-Silva SF, Reis MA, Patrício LR, Gavioli CF, Miranda AE: Late diagnosis and HIV infection in children attending a service of specialized care for pediatric AIDS in Brazil. Rev Soc Bras Med Trop 2014, 47(1):93-6.
• [16]Peacock-Villada E, Richardson BA, John-Stewart GC: Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics 2011, 127:e423-41.
• [17]Joint United Nations Programme on HIV/AIDS (UNAIDS): Global report: UNAIDS report on the global AIDS epidemic 2012. “UNAIDS/JC2417E”. WHO, Geneva; 2012.
• [18]Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.: Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-44.
• [19]World Health Organization: Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2010 revision. World Health Organization, Geneva; 2010.
• [20]Yoshimoto CE, Diniz EM, Vaz FA: Clinical and laboratory evolution of children born to HIV positive mothers. Rev Assoc Med Bras 2005, 51:100-5.
• [21]Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee: Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis AIDS 2008, 22:97-105.
• [22]Cardoso CA, Pinto JA, Candiani TM, Carvalho IR, Dantas AG, Goulart EM: Assessment of the prognostic value of the World Health Organization clinical staging system for HIV/AIDS in HIV-infected children and adolescents in a cohort in Belo Horizonte, Brazil. J Trop Pediatr 2012, 58:353-9.
• [23]Brasil. Sistema de Informação de Mortalidade. Available at: http://svs.aids.gov.br/cgiae/sim/. Accessed November 11, 2012.
• [24]Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS: Critérios de definição de casos de AIDS em adultos e crianças. 2ª edição. (Série Manuais n. 60:30–33). Ministério da Saúde, Brasília; 2003.
• [25]Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, et al.: Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis 2010, 51:1449-57.
• [26]Brasil. Ministério da Saúde, 2012. Boletim Epidemiológico – AIDS e DST. Ano VIII – n 1. Available at: www.aids.gov.br.
• [27]Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, et al.: Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort. (EPF/ANRS CO10). Clin Infect Dis 2010, 51:214-24.
• [28]Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al.: Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One 2011, 6:e19261.
• [29]Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al.: Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998, 279:756-61.
• [30]Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, et al.: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1–infected children. National Institute of child health and human development intravenous immunoglobulin clinical trial study group. J Infect Dis 1997, 175:1029-38.
• [31]Soeiro CM, Miranda AE, Saraceni V, Talhari S, Ferreira LC: Clinical aspects of pediatric AIDS cases notified in the state of Amazonas, 1991–2009. Braz J Infect Dis 2011, 15:411-2.